Open the medication list on any large GLP-1 program and you will see brand pens, brand pills, compounded injections, compounded pills, drops, microdoses and, on some, the words "same active ingredient". They are not the same thing, they do not come from the same place, and the questions you should ask differ for each. This page sorts the list.
The sort
Read each line on the program's medication list and put it in one of three bins.
Bin 1, brand. Wegovy (pen or pill), Ozempic, Rybelsus, Zepbound (pen or vial), Mounjaro, Foundayo, Saxenda, Victoza. FDA-approved products. The program is arranging a prescription and routing it to a pharmacy (sometimes the manufacturer's direct channel, sometimes a mail-order partner, sometimes yours). The price on the page is the pharmacy's cash price or your insurance copay, and the program's own fee is separate.
Bin 2, compounded. Anything described as compounded semaglutide, compounded tirzepatide, or a form that does not exist as an approved product: oral kits, sublingual drops, dissolving tablets, "microdose", combinations with B12 or other additives. Made under section 503A (a pharmacy, on a patient-specific prescription) or 503B (an outsourcing facility, under FDA registration) and not FDA approved. The FDA has stated that these products are not evaluated for safety, effectiveness or quality before marketing and are not interchangeable with the approved products. Many programs print a version of that sentence; the rubric's sourcing criterion checks that they do.
Bin 3, neither. Anything with "research", "laboratory" or "not for human consumption" in the description. Not a medication for you. See the red flags checklist.
What the bin changes
The pharmacy question
For bin 1, the question is which pharmacy dispenses and whether you can choose your own. For bin 2, it is the whole question: which 503A pharmacy or 503B facility, licensed where, tested how, and will they show you the certificate of analysis. Programs that sell both often answer the first well and the second not at all.
The price question
Brand prices on a program page are, in the cases we evaluated, either the manufacturer's self-pay price passed through (with LillyDirect and NovoCare Pharmacy as the reference points) or a mail-order pharmacy's price. Compounded prices are set by the program and the pharmacy together and vary by dose in ways the page may not show. Ask for the price at the dose most people reach by month four, in both bins. The GLP-1 cost report from FormBlends and the sibling pricing index track published prices with dates.
The "same active ingredient" claim
You will see it on compounded pages. It is true in the narrow sense that semaglutide is semaglutide, and misleading in every other sense: the compounded product has not been through the approval process, may use a different formulation, and in some cases the FDA has found salt forms that are not the same substance. The September 2025 FDA warning letters to Hims and Hers, linked from the Hims and Hers evaluation, addressed claims that implied equivalence to Ozempic and Wegovy. A page that leans on "same active ingredient" without the not-FDA-approved sentence beside it has made a choice.
After the shortages
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025 (the dates and what changed are on the sibling site's shortage timeline). Since then, compounding a product that is essentially a copy of an approved drug is restricted, and in February 2026 the FDA announced it intended to act against mass-marketed non-approved GLP-1s. Several programs on this site have moved to brand-only lists or to compounded forms that differ from the approved products (oral kits, microdoses, additives). Whether a given compounded product is lawful is a question for the pharmacy's board and its lawyer, not for a marketing page, and not for us. The rubric asks only whether the program tells you what it is.
A one-minute test
Find the medication list. Count the lines in each bin. Then find the sentence that says compounded products are not FDA approved. If bin 2 has entries and that sentence is not on the same page, the program has scored itself.
Questions people ask
Is 'oral semaglutide' brand or compounded?
Either. Rybelsus and the Wegovy pill are FDA-approved oral semaglutide products from Novo Nordisk. Compounded oral kits, sublingual drops and dissolving tablets sold by telehealth programs are compounded and not FDA approved. The word oral tells you nothing; the brand name or the word compounded does.
What is a microdose program?
A marketing term for compounded GLP-1 at doses below the labelled starting dose of the approved products. There is no FDA-approved microdose product. Ask which pharmacy makes it, at what concentration, and who chose the dose.
Sources
- FDA: Human Drug Compounding Accessed September 4, 2026.
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss Accessed September 4, 2026.
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize Accessed September 4, 2026.
- GLP-1 cost report 2026 (FormBlends) Accessed September 4, 2026.
Canonical URL: https://formblendsreviews.com/guides/brand-vs-compounded-on-a-program-page. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.